• Fri, May 21, 2021
• Mon, May 24, 2021
Eliana Merle Initiated (BBIO) at Strong Buy and Held Target at $80 on, May 21st, 2021
Eliana Merle of UBS, Initiated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $80 on, May 21st, 2021.
Eliana has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Eliana's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Eliana
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $80 on, Friday, May 7th, 2021
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $75 on, Tuesday, March 23rd, 2021
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $86 on, Thursday, March 4th, 2021
Like: 👍
